Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-535-4 | CAS number: 84-51-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- based on test type (migrated information)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- from 2012-02-16 until 2012-11-14
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline-conform study performed under GLP
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- 2-ethylanthraquinone
- EC Number:
- 201-535-4
- EC Name:
- 2-ethylanthraquinone
- Cas Number:
- 84-51-5
- Molecular formula:
- C16H12O2
- IUPAC Name:
- 2-ethyl-9,10-anthraquinone
- Details on test material:
- - Name of test material (as cited in study report): 2-ETHYLANTHRAQUINONE
- Physical state: yellow solid flakes
- Analytical purity: 98.83%
- Impurities (identity and concentrations): not reported
- Purity test date: not reported
- Lot/batch No.: 110929
- Expiration date of the lot/batch: 31 December 2012
- Stability under test conditions: not reported
- Storage condition of test material: room temperature in the dark
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories U.K.Ltd.; Blackthorn, Bicster, Oxon, UK
- Age at study initiation: (P) 12 wks
- Weight at study initiation: (P) Males: 316-366 g; Females: 189-222 g
- Fasting period before study: none
- Housing: groups of five, during pairing phase one male:one female
- Diet (e.g. ad libitum): ad libitum, Rodent 2018C Tejlad Global Certified Diet, Harlan
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 -23
- Humidity (%): 40 - 70 %
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 21. March 2012 To: 5. May 2012
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE
- Justification for use and choice of vehicle (if other than water): arachis oil BP
- Concentration in vehicle: 1.25 mg/mL, 5 mg/mL and 25 mg/mL for low, mid and high dose administration
- Amount of vehicle (if gavage): 4 mL/kg - Details on mating procedure:
- - M/F ratio per cage: 1/1
- Length of cohabitation: max 14 days
- Proof of pregnancy: vaginal plug or presence of sperm in vagina referred to as day 0 of pregnancy
- After successful mating each pregnant female was caged (how): individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of the test substance in the test item formulation was verified by high performance liquid chromatography (HPLC) using an external standard technic. The formulation were extracted with methanol to give a final theoretical concentration of 0.01 mg/mL.
The test item formulations were mixed thoroughly and samples were taken from the bottom, the middle and the top of the container., shaking between sampling. Sampling was performed in triplicates.
Stability, homogeneity and correctness of the prepared concentrations were analysed. - Duration of treatment / exposure:
- Exposure period males: 43 days
Exposure period females: 43-45 days
Premating exposure period (males): 14 days
Premating exposure period (females): 14 days - Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 5, 20 and 100 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 10 rats
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: base on the results of previous toxicity work
- Positive control:
- no
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: all animals were examined for overt signs of toxicity, ill-health and behavioural changes immediately before dosing, up to 30 minutes after dosing, and one and five hours after dosing, during working days. On weekend and public holidays animals were observed immediately before dosing, soon after dosing, and one hours after dosing (except for females after parturition where applicable).
DETAILED CLINICAL OBSERVATIONS: Yes
- prior to start of treatment and then weekly. All animals were observed for signs of functional/behavioural toxicity. Functional performance test 8motor activity, forelimb/hindlimb grip strength) and assessment of sensory reactivity were performed on 5/sex/dose prior to termination.
BODY WEIGHT: Yes
- Time schedule for examinations: day 1 prior to dosing, and then weekly for males until termination and weekly for females until mating was evident. After this body weight was recorded for females on day 7, 14 and 20 post coitum, and on day 1 and 4 post partum.
FOOD CONSUMPTION :
- Food consumption for each cage determined weekly during pre-mating period and continued for males after mating period. For females after evidence of mating, food consumption was recorded for the periods covering post coitum days 0-7, 7-14 and 14-20. For females with litters, food consumption was recorded on day 1 and 4 pp.
WATER CONSUMPTION: Yes
- Time schedule for examinations: daily with exception of pairing phase
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: prior of termination
- Anaesthetic used for blood collection: No data
- Animals fasted: No
- How many animals: 5/sex/group
- Parameters checked in table 2 were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: prior of termination
- Animals fasted: No
- How many animals: 5/sex/group
- Parameters checked in table 2 were examined.
URINALYSIS: Yes, from 5 males/group
- Time schedule for collection of urine: final week of treatment
- Metabolism cages used for collection of urine: No data
- Animals fasted: No
- Parameters checked: under table 2 were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: functional/behaviour toxicity in all animals prior treatment and with weekly intervall. Functional performance test was performed in 5/sex/group prior to termination.
- Dose groups that were examined: all groups
- Battery of functions tested: sensory activity, grip strength , motor activity - Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals
- Maternal animals: All surviving animals
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, and abdominal viscera.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 1 were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- SACRIFICE
- all offspring were sacrificed at 5 days of age.
- These animals were subjected to postmortem examinations as follows:
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations - Statistics:
- Bartlett's test was used for analysing homogeneity of variance from mean values. Intergroup variance were assessed using ANOVA or ANCOVA. Williams test for parametric data, Shirley test for non-parametric data, or if no dose response was found data were analysed by stepwise Dunnett's (parametric) or Steel (non-parametric) test. Pair-wise test was performed using Student t-test (parametric) or Mann-Whitney U test (non-parametric).
- Reproductive indices:
- pre-coital indices; fertility indices (mating index and pregnancy index), gestation length, parturition index, implantation losses (pre-implantation and post-implantation losses)
- Offspring viability indices:
- live birth index, viability index, sex ratio
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- reduced body weight gain, reduced food consumption in females, increased water consumption in males
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- reduced body weight gain, reduced food consumption in females, increased water consumption in males
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- extramedullary hemopoiesis in spleen, hepatocellular hypertrophy, increase incidence of hyaline droplets in kidneys in males
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
Details on results (P0)
Effect levels (P0)
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- repeated dose toxicity
- Effect level:
- >= 20 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Dose descriptor:
- NOAEL
- Remarks:
- fertility
- Effect level:
- >= 100 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment related findings in the fertility of parents
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- no effects observed
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
Effect levels (F1)
- Dose descriptor:
- NOAEL
- Remarks:
- teratogenicity
- Generation:
- F1
- Effect level:
- >= 100 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment related findings in offspring
Overall reproductive toxicity
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
Table 3: Summary Incidence of Daily Clinical Observation
Findings |
Group 1 0 mg/kg bw/d |
Group 2 5 mg/kg bw/d |
Group 3 20 mg/kg bw/d |
Group 4 100 mg/kg bw/d |
||||
Treatment/No of animals |
10 M |
10 F |
10 M |
10 F |
10 M |
10 F |
10 M |
10 F |
Scheduled kill |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
9 |
found dead |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 (after bleeding) |
increased salivations |
0 |
0 |
0 |
0 |
6 |
4 |
10 |
10 |
Generalised fur loss |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
M: Males; F: Females
Table 4: Necropsy findings
Findings |
Group 1 0 mg/kg bw/d |
Group 2 5 mg/kg bw/d |
Group 3 20 mg/kg bw/d |
Group 4 100 mg/kg bw/d |
||||
No of findings/No of animals |
10 M |
10 F |
10 M |
10 F |
10 M |
10 F |
10 M |
9 F |
Epididymides, small, left |
0/10 |
- |
0/10 |
- |
0/10 |
- |
1/10 |
- |
Kidneys, increased pelvic space, right |
0/10 |
- |
0/10 |
- |
0/10 |
- |
1/10 |
- |
Testes, small, left |
0/10 |
- |
0/10 |
- |
0/10 |
- |
1/10 |
- |
Liver, malformed left lobe |
- | 0/10 | - | 0/10 | - | 1/10 | - | 0/9 |
Liver, malformed median lobe |
- | 0/10 | - | 1/10 | - | 0710 | - | 0/9 |
Lungs, reddened |
- | 1/10 | - | 0/10 | - | - | 1/9 | |
Spinal cord, mass mid-thoracic |
- | 1/10 | - | 0/10 | - | 0/10 | - | 0/10 |
M: Males; F: Females
Table 5: Histopathology findings
Findings |
Group 1 0 mg/kg bw/d |
Group 2 5 mg/kg bw/d |
Group 3 20 mg/kg bw/d |
Group 4 100 mg/kg bw/d |
||||
Incidence/Mean Severity |
5 M |
5 F |
5 M |
5 F |
5 M |
6F |
5 M |
5 F |
Liver: Hepathocellular hypertrophy |
- |
- |
- |
- |
- |
- |
3/1.0 |
2/1.0 |
Spleen: Extramedullary hemopoiesis |
5/1.0 |
5/2.0 |
5/1.0 |
5/2.0 |
5/1.4 |
5/2.2 |
5/1.8 |
5/2.8 |
Kidney: Hyaline droplets |
1/1.0 |
- |
2/1.0 |
- |
2/1.0 |
- |
1/10 |
- |
Kidne: Tubular basophilia | 1/1.0 | - | 2/1.0 | - | 1/1.0 | 2/1.0 | 5/1.0 | 1/1.0 |
M: Males; F: Females
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study, the NOAEL for reproduction/ developmental toxicity was considered to be 100 mg/kg/day for parent and offspring.
The NOAEL for repreated dose toxicity is considered to be 20 mg/kg bw for the rat under the conditions of this study. - Executive summary:
2 -ethylanthraquinone was tested in a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test in rats with application via the oral route according to OECD Guideline 422 and GLP. The test substance was administered as a solution in Arachis oil BP orally by gavage to 3 groups of 10 male and 10 female Wistar rats each, once a day on 7 days per week for 43 - 45 consecutive days.
Doses used:
• Group 2 (low dose): 5 mg per kg body weight and day,
• Group 3 (mid dose): 20 mg per kg body weight and day,
• Group 4 (high dose): 100 mg per kg body weight and day.
An equally sized negative control group (group 1) received Arachis oil BP, the vehicle for the test substance. The duration of treatment covered a 2 -week pre-mating period in both sexes, the mating period, the gestation period as well as 4 days of lactation in females and treatment up to day 43 for males.
One unscheduled death occurred in the high dose female group on day of termination after bleeding. All other animals survived until termination. No treatment related effects could be observed on reproductive/developmental parameters. Therefore the NOAEL for reproductive toxicity was considered to be 100 mg/kg bw.
The NOAEL for general, systemic parental toxicity of the test substance was determined to be 20 mg/kg bw/day based on adverse clinical pathological findings at next higher dose (reduced body weight gain, reduced food consumption in females, changes in haematology, increased extramedullary hemopoiesis in spleen, increased spleen weight, increase bile acid in males and total protein in females). Changes in liver weight connected with hepatocellular hypertrophy is commonly observed in rat liver following administration of xenobiotics and does not represent an adverse effect. Increase incidence of hyaline droplets in kidneys of males is a well known response to treatment with some hydrocarbons and known to represent limited relevance to human.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.